Retrophin, a biopharmaceutical company, has a focus on developing and providing innovative treatments for individuals with rare diseases. Its primary product candidate in late-stage development is sparsentan, which has the potential to treat focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), both rare disorders of the kidney that often lead to end-stage kidney disease. Retrophin is also conducting research in other rare diseases in conjunction with patient advocacy groups and government research entities, including NGLY1 deficiency and Alagille syndrome. Retrophin’s commercial products, Chenodal, Cholbam, Thiola, and Thiola EC, provide the necessary revenue to support their research and development efforts.